Wechselwirkungen · Volibris
Volibris 2.5 mg film-coated tablets Volibris 5 mg film-coated tablets Volibris 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-118976 · Präparat HOS-094889
The efficacy and safety of ambrisentan when co-administered with other treatments for PAH (e.g. prostanoids and soluble guanylate cyclase stimulators) has not been specifically studied in controlled clinical trials in PAH patients (see section 5.1). No specific interactions between ambrisentan and soluble guanylate cyclase stimulators or prostanoids are anticipated based on the known biotransformation data (see section 5.2). However, no specific interactions studies have been conducted with these medicinal products. Therefore, caution is recommended in the case of co- administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-22T14:55:00Z · SHA-256 5c01ef1f81a8078355d1d9b164dc55e270b4c22e60736bc4ee1b622689a8bc09 · Passage 4435c459d4fa586c0bf06edc53adce25c810fd8866de499272a884f93bee09f4 · Zeichen 2156–2746 im Abschnitt